Lixte Biotechnology Holdings, Inc. (LIXTW)

Market Cap	26.05M
Revenue (ttm)	n/a
Net Income (ttm)	-3.32M
Shares Out	2.68M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,169
Open	0.2289
Previous Close	0.2300
Day's Range	0.2100 - 0.2500
52-Week Range	0.0190 - 0.3800
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 8, 2025

About CTIC

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: LIXTW
• Website: https://lixte.com